Thus, in the future, elevated levels of expression of CYC1 and UQBP could be used to identify high-risk ER(+) and ER(−) breast cancer patients that might benefit from treatment with atovaquone, a complex III inhibitor. Here, CYC1 is linked to breast carcinoma.